How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

685 results for

Pulmonary Hypertension in Sickle Cell Anemia

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. Sickle Cell Anemia (Treatment)

regular blood transfusions (to reduce HbS to < 30%-50% total hemoglobin), hydroxyurea, or bypass surgery for advanced occlusive disease. [ ] Transfusion therapy, aimed at keeping the proportion of HbS below 30%, is now considered standard care for primary and secondary stroke prevention in children with SCD. The Stroke Prevention Trial in Sickle Cell Anemia (STOP) showed that regular blood transfusions produced a marked (90%) reduction in first stroke in asymptomatic high-risk children who had 2 (...) , and a history of priapism. Even modestly increased pulmonary artery pressures are associated with severe reduction in exercise capacity, as assessed by both the 6-minute walk and cardiopulmonary exercise testing, and herald a poor prognosis. Both pulmonary hypertension and cardiac sequelae, such as diastolic dysfunction, have been associated with accelerated mortality in the sickle cell disease population. For symptomatic patients, hydroxyurea and chronic transfusion have been used. Enothelin-1 receptor

2014 eMedicine Pediatrics

82. Sickle Cell Anemia (Overview)

) to identify these conditions in young patients. [ ] In the study, 17 patients (43.6%) had ambulatory hypertension, whereas 4 (10.3%) had hypertension on the basis of their clinic blood pressure. Twenty-three patients (59%) had impaired systolic blood pressure dipping, 7 (18%) had impaired diastolic blood pressure dipping, and 5 (13%) had reversed dipping. [ ] Imaging studies Imaging studies that aid in the diagnosis of sickle cell anemia in patients in whom the disease is suggested clinically include (...) P, Godeau B, et al. Acute kidney injury in sickle patients with painful crisis or acute chest syndrome and its relation to pulmonary hypertension. Nephrol Dial Transplant . 2010 Aug. 25(8):2524-9. . Scheinman JI. In: Holliday M, Barratt TM, Avner ED (Eds.). Sickle cell nephropathy . Baltimore: Williams and Wilkins; 1994. Pediatric Nephrology: 908. Nissenson AR, Port FK. Outcome of end-stage renal disease in patients with rare causes of renal failure. I. Inherited and metabolic disorders. Q J Med

2014 eMedicine Pediatrics

83. Anemia, Sickle Cell (Diagnosis)

) to identify these conditions in young patients. [ ] In the study, 17 patients (43.6%) had ambulatory hypertension, whereas 4 (10.3%) had hypertension on the basis of their clinic blood pressure. Twenty-three patients (59%) had impaired systolic blood pressure dipping, 7 (18%) had impaired diastolic blood pressure dipping, and 5 (13%) had reversed dipping. [ ] Imaging studies Imaging studies that aid in the diagnosis of sickle cell anemia in patients in whom the disease is suggested clinically include (...) P, Godeau B, et al. Acute kidney injury in sickle patients with painful crisis or acute chest syndrome and its relation to pulmonary hypertension. Nephrol Dial Transplant . 2010 Aug. 25(8):2524-9. . Scheinman JI. In: Holliday M, Barratt TM, Avner ED (Eds.). Sickle cell nephropathy . Baltimore: Williams and Wilkins; 1994. Pediatric Nephrology: 908. Nissenson AR, Port FK. Outcome of end-stage renal disease in patients with rare causes of renal failure. I. Inherited and metabolic disorders. Q J Med

2014 eMedicine Emergency Medicine

84. Sickle Cell Anemia (Follow-up)

regular blood transfusions (to reduce HbS to < 30%-50% total hemoglobin), hydroxyurea, or bypass surgery for advanced occlusive disease. [ ] Transfusion therapy, aimed at keeping the proportion of HbS below 30%, is now considered standard care for primary and secondary stroke prevention in children with SCD. The Stroke Prevention Trial in Sickle Cell Anemia (STOP) showed that regular blood transfusions produced a marked (90%) reduction in first stroke in asymptomatic high-risk children who had 2 (...) , and a history of priapism. Even modestly increased pulmonary artery pressures are associated with severe reduction in exercise capacity, as assessed by both the 6-minute walk and cardiopulmonary exercise testing, and herald a poor prognosis. Both pulmonary hypertension and cardiac sequelae, such as diastolic dysfunction, have been associated with accelerated mortality in the sickle cell disease population. For symptomatic patients, hydroxyurea and chronic transfusion have been used. Enothelin-1 receptor

2014 eMedicine Pediatrics

85. Sickle Cell Anemia (Diagnosis)

) to identify these conditions in young patients. [ ] In the study, 17 patients (43.6%) had ambulatory hypertension, whereas 4 (10.3%) had hypertension on the basis of their clinic blood pressure. Twenty-three patients (59%) had impaired systolic blood pressure dipping, 7 (18%) had impaired diastolic blood pressure dipping, and 5 (13%) had reversed dipping. [ ] Imaging studies Imaging studies that aid in the diagnosis of sickle cell anemia in patients in whom the disease is suggested clinically include (...) P, Godeau B, et al. Acute kidney injury in sickle patients with painful crisis or acute chest syndrome and its relation to pulmonary hypertension. Nephrol Dial Transplant . 2010 Aug. 25(8):2524-9. . Scheinman JI. In: Holliday M, Barratt TM, Avner ED (Eds.). Sickle cell nephropathy . Baltimore: Williams and Wilkins; 1994. Pediatric Nephrology: 908. Nissenson AR, Port FK. Outcome of end-stage renal disease in patients with rare causes of renal failure. I. Inherited and metabolic disorders. Q J Med

2014 eMedicine Pediatrics

86. Anemia, Sickle Cell (Overview)

) to identify these conditions in young patients. [ ] In the study, 17 patients (43.6%) had ambulatory hypertension, whereas 4 (10.3%) had hypertension on the basis of their clinic blood pressure. Twenty-three patients (59%) had impaired systolic blood pressure dipping, 7 (18%) had impaired diastolic blood pressure dipping, and 5 (13%) had reversed dipping. [ ] Imaging studies Imaging studies that aid in the diagnosis of sickle cell anemia in patients in whom the disease is suggested clinically include (...) P, Godeau B, et al. Acute kidney injury in sickle patients with painful crisis or acute chest syndrome and its relation to pulmonary hypertension. Nephrol Dial Transplant . 2010 Aug. 25(8):2524-9. . Scheinman JI. In: Holliday M, Barratt TM, Avner ED (Eds.). Sickle cell nephropathy . Baltimore: Williams and Wilkins; 1994. Pediatric Nephrology: 908. Nissenson AR, Port FK. Outcome of end-stage renal disease in patients with rare causes of renal failure. I. Inherited and metabolic disorders. Q J Med

2014 eMedicine Emergency Medicine

87. Anemia, Sickle Cell (Follow-up)

regular blood transfusions (to reduce HbS to < 30%-50% total hemoglobin), hydroxyurea, or bypass surgery for advanced occlusive disease. [ ] Transfusion therapy, aimed at keeping the proportion of HbS below 30%, is now considered standard care for primary and secondary stroke prevention in children with SCD. The Stroke Prevention Trial in Sickle Cell Anemia (STOP) showed that regular blood transfusions produced a marked (90%) reduction in first stroke in asymptomatic high-risk children who had 2 (...) , and a history of priapism. Even modestly increased pulmonary artery pressures are associated with severe reduction in exercise capacity, as assessed by both the 6-minute walk and cardiopulmonary exercise testing, and herald a poor prognosis. Both pulmonary hypertension and cardiac sequelae, such as diastolic dysfunction, have been associated with accelerated mortality in the sickle cell disease population. For symptomatic patients, hydroxyurea and chronic transfusion have been used. Enothelin-1 receptor

2014 eMedicine Emergency Medicine

88. Anemia, Sickle Cell (Treatment)

regular blood transfusions (to reduce HbS to < 30%-50% total hemoglobin), hydroxyurea, or bypass surgery for advanced occlusive disease. [ ] Transfusion therapy, aimed at keeping the proportion of HbS below 30%, is now considered standard care for primary and secondary stroke prevention in children with SCD. The Stroke Prevention Trial in Sickle Cell Anemia (STOP) showed that regular blood transfusions produced a marked (90%) reduction in first stroke in asymptomatic high-risk children who had 2 (...) , and a history of priapism. Even modestly increased pulmonary artery pressures are associated with severe reduction in exercise capacity, as assessed by both the 6-minute walk and cardiopulmonary exercise testing, and herald a poor prognosis. Both pulmonary hypertension and cardiac sequelae, such as diastolic dysfunction, have been associated with accelerated mortality in the sickle cell disease population. For symptomatic patients, hydroxyurea and chronic transfusion have been used. Enothelin-1 receptor

2014 eMedicine Emergency Medicine

89. A Phase II Trial of Regadenoson in Sickle Cell Anemia

individuals with sickle cell anemia (SCA) and pain or acute chest syndrome (ACS) compared to placebo. Patients were classified as having an improvement in respiratory symptoms if they experienced any of the following outcomes:(1) respiratory rate decreased by 25% from baseline or normalized (≤20 bpm) or (2) degree of hypoxia (SpO2) on room air increased by 10% from baseline or normalized (≥92%) or (3) thoracic pain improved by 3 points from baseline on a 10-point visual analog scale. Opioid Use [ Time (...) Details Study Description Go to Brief Summary: This research study is a Phase II clinical trial, which tests the safety and effectiveness of an investigational drug called Regadenoson (or Lexiscan) to learn whether the drug works in treating a specific disease, in this case Sickle Cell Disease (SCD). "Investigational" means that the drug is being studied. It also means that the FDA has not yet approved the drug for your type of disease. SCD is an inherited blood disorder that causes the red blood

2013 Clinical Trials

90. Nonmyeloablative Conditioning for Mismatched Hematopoietic Stem Cell Transplantation for Severe Sickle Cell Disease

to the date of an event or last follow-up. An event is defined as toxicity (graft failure, death) or a disease-related event (stroke, acute chest syndrome, pain crisis) with full recipient-type hemoglobin on hemoglobin electrophoresis for patients with sickle cell disease. Event-free survival rate [ Time Frame: 2 years ] -Event-free survival (EFS) is defined as the date of transplant to the date of an event or last follow-up. An event is defined as toxicity (graft failure, death) or a disease-related (...) event (stroke, acute chest syndrome, pain crisis) with full recipient-type hemoglobin on hemoglobin electrophoresis for patients with sickle cell disease. Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided

2016 Clinical Trials

91. Oxidized Mutant Human Hemoglobins S and E Induce Oxidative Stress and Bioenergetic Dysfunction in Human Pulmonary Endothelial Cells Full Text available with Trip Pro

Oxidized Mutant Human Hemoglobins S and E Induce Oxidative Stress and Bioenergetic Dysfunction in Human Pulmonary Endothelial Cells Cell free hemoglobin (Hb), becomes oxidized in the circulation during hemolytic episodes in sickle cell disease (SCD) or thalassemia and may potentially cause major complications that are damaging to the vascular system. Hemolytic anemias are commonly associated with pulmonary hypertension (PH) and often result from dysfunction of lung endothelial cells. The aim (...) of this study was to determine the effect of different Hbs on cultured human lung endothelial function. Toward this goal, endothelial permeability, oxidative stress response parameters, glycolytic and mitochondrial bioenergetic functions were monitored in cultured human pulmonary arterial endothelial cells (HPAEC) following incubation with human adult Hb (HbA), and Hb isolated from patients with sickle cell Hb (HbS, βV6E) and HbE (βE26K) that commonly co-exist with β-thalassemia. These mutant Hbs are known

2017 Frontiers in physiology

92. Microvascular Blood Flow in Sickle Cell Anemia

Microvascular Blood Flow in Sickle Cell Anemia Microvascular Blood Flow in Sickle Cell Anemia - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Microvascular Blood Flow in Sickle Cell Anemia The safety (...) at Chicago Oregon Health and Science University Dana-Farber Cancer Institute Information provided by (Responsible Party): Joshua Field, Medical College of Wisconsin Study Details Study Description Go to Brief Summary: Sickle cell disease (SCD) is an inherited blood disorder that causes the red blood cells to change their shape from a round shape to a half-moon/crescent or sickled shape. Sickle-shaped cells can cause problems by getting stuck in blood vessels, blocking blood flow, and can cause

2012 Clinical Trials

93. Tissue Doppler Echocardiographic Findings of Left Ventricle in Children with Sickle-Cell Anemia Full Text available with Trip Pro

Tissue Doppler Echocardiographic Findings of Left Ventricle in Children with Sickle-Cell Anemia Sickle-cell disease (SCD) is an inherited hemoglobin childhood disorder, frequently complicated by pulmonary hypertension and cardiac involvement. Cardiovascular events and complications are the leading cause of mortality and morbidity in patients with SCD. Tissue Doppler imaging and the myocardial performance index (Tei index), are simple indices for the assessment of the cardiac function (...) between the two groups (p value < 0.038).The Tei index is a sensitive indicator for the cardiac function in chronic diseases and the right ventricular function in some disorders such as SCD.

2012 The Journal of Tehran University Heart Center

94. The diagnosis and management of primary autoimmune haemolytic anaemia

Journal of Medicine, 56, 61- 69. Hansen,K.E., Wilson,H.A., Zapalowski,C., Fink,H.A., Minisola,S., & Adler,R.A. (2011) Uncertainties in the prevention and treatment of glucocorticoid-induced osteoporosis. J Bone Miner.Res, 26, 1989-1996. Heisel,M.A. & Ortega,J.A. (1983) Factors influencing prognosis in childhood autoimmune hemolytic anemia. American Journal of Pediatric Hematology/Oncology, 5, 147-152. Hendrick,A.M. (2003) Auto-immune haemolytic anaemia--a high-risk disorder for thromboembolism (...) IgG antibody which binds to red cells at low temperature and causes complement mediated lysis as the temperature is raised. The DAT is usually positive to C3 only. There may be agglutination, spherocytes or erythrophagocytosis by neutrophils on blood film. Reticulocytopenia is common early in PCH evolving into reticulocytosis with recovery. PCH can be diagnosed in patients with AIHA and a positive Donath-Landsteiner test. The test can be technically difficult (Sokol et al, 1999) and false negative

2016 British Committee for Standards in Haematology

95. Guidelines on Diagnosis and Treatment of Pulmonary Hypertension

exposure to high altitude 3.7 Developmental abnormalities 4 Chronic thromboembolic pulmonary hypertension 5 PH with unclear and/or multifactorial mechanisms 5.1 Haematological disorders: myeloproliferative disorders, splenectomy. 5.2 Systemic disorders: sarcoidosis, pulmonary Langerhans cell histiocytosis, lymphangioleiomyomatosis, neuro?bromatosis, vasculitis 5.3 Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders 5.4 Others: tumoural obstruction, ?brosing mediastinitis (...) . . . . . . . . . . . . . . . . . . . . . . 2502 7.1.6 Ventilation/perfusion lung scan . . . . . . . . . . . . . 2504 7.1.7 High-resolution computed tomography, contrast- enhanced computed tomography, and pulmonary angiography . . . . . . . . . . . . . . . . . . . . . . . . . . 2504 7.1.8 Cardiac magnetic resonance imaging. . . . . . . . . . 2505 7.1.9 Blood tests and immunology . . . . . . . . . . . . . . . 2505 7.1.10 Abdominal ultrasound scan . . . . . . . . . . . . . . . 2505 7.1.11 Right heart catheterization and vasoreactivity

2009 European Society of Cardiology

96. Pulmonary capillary hemangiomatosis: an uncommon cause of pulmonary hypertension Full Text available with Trip Pro

Gláucia G Marchiori Edson E eng por Letter Comment Brazil J Bras Pneumol 101222274 1806-3713 0 Phosphodiesterase 5 Inhibitors 0 Piperazines 0 Sulfones IM J Bras Pneumol. 2011 Mar-Apr;37(2):272-6 21537664 J Bras Pneumol. 2012 Jan-Feb;38(1):143-4 22407053 Anemia, Sickle Cell complications Female Humans Hypertension, Pulmonary drug therapy etiology Phosphodiesterase 5 Inhibitors therapeutic use Piperazines therapeutic use Schistosomiasis complications Sulfones therapeutic use 2013 7 17 6 0 2013 7 17 6 0 (...) Pulmonary capillary hemangiomatosis: an uncommon cause of pulmonary hypertension 23857691 2014 05 07 2018 12 02 1806-3756 39 3 2013 May-Jun Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia J Bras Pneumol Pulmonary capillary hemangiomatosis: an uncommon cause of pulmonary hypertension. 390-2 10.1590/S1806-37132013000300019 S1806-37132013000300390 Faria Igor Murad IM Carneiro Leonardo Hoehl LH Tiradentes Teófilo Augusto Araújo TA Zanetti

2013 Jornal brasileiro de pneumologia : publicaça̋o oficial da Sociedade Brasileira de Pneumologia e Tisilogia

97. Autologous hematopoietic cell transplantation for autoimmune diseases

is a provincial initiative of CCO supported by the Ontario Ministry of Health and Long-Term Care (OMHLTC). All work produced by the PEBC is editorially independent from the OMHLTC. INTRODUCTION Hematopoietic cell transplantation (HCT), formerly known as stem cell transplantation, is a treatment for patients with malignant diseases such as lymphoma, leukemia, and myeloma, and for other acquired and genetic non-malignant hematological (blood), immunological, and storage disorders. Transplantation involves (...) administration of high-dose chemotherapy, sometimes accompanied by total body radiation, to destroy the diseased cells. Because this destroys the patient's bone marrow, hematopoietic stem cells are infused to regenerate the marrow and to produce healthy blood and immune cells. Allogeneic HCT uses a donor as the source of these bone marrow-derived stem cells. Autologous HCT (aHCT) involves harvesting the patient’s own hematopoietic stem cells before treatment then transplanting the stem cells back

2019 Cancer Care Ontario

98. Macrolide Therapy to Improve Forced Expiratory Volume in 1 Second in Adults With Sickle Cell Disease

insufficient resources to initiate the trial.) First Posted : November 9, 2016 Last Update Posted : October 2, 2018 Sponsor: Vanderbilt University Information provided by (Responsible Party): Michael DeBaun, Vanderbilt University Study Details Study Description Go to Brief Summary: Sickle cell anemia (SCA) is a life-threatening, monogenic disorder associated with early death when compared to individuals without SCA. Pulmonary complications, namely acute chest syndrome, obstructive lung disease (...) Participant Data (IPD) Sharing Statement: Plan to Share IPD: Yes Keywords provided by Michael DeBaun, Vanderbilt University: sickle cell disease pulmonary complications reduced FEV1 azithromycin lung function Additional relevant MeSH terms: Layout table for MeSH terms Anemia, Sickle Cell Anemia, Hemolytic, Congenital Anemia, Hemolytic Anemia Hematologic Diseases Hemoglobinopathies Genetic Diseases, Inborn

2016 Clinical Trials

99. Hydroxyurea in the Treatment of Sickle Cell Disease

hemoglobin level, hemoglobin S level, white blood count, platelet count, lactate dehydrogenase level, total and direct bilirubin levels, aspartate and alanine aminotransferase levels, and serum creatinine level. The incidence of complications pre- and post-hydroxyurea therapy will be also analyzed including: stroke, silent cerebral infraction, acute chest syndrome, vaso-occlusive crisis, hospitalization, pulmonary hypertension, leg ulcers, bone necrosis, and kidney injury. Safety data included adverse (...) of stroke, silent cerebral infraction, acute chest syndrome, vaso-occlusive crisis, pulmonary hypertension, leg ulcers, bone necrosis and kidney injury will be evaluated. Rate of hospitalizations [ Time Frame: An average of 3 years before and an average of 3 years after initiation of hydroxyurea therapy ] Changing in rate of hospitalizations before and after start hydroxyurea therapy Secondary Outcome Measures : Changing in the incidence of complications according to specific subgroups [ Time Frame

2016 Clinical Trials

100. Transplantation Using Reduced Intensity Approach for Patients With Sickle Cell Disease From Mismatched Family Donors of Bone Marrow

a platelet count > 50,000/µL and did not receive a platelet transfusion in the previous 7 days. Chimerism Rate following Hematopoietic Cell Transplantation for Sickle Cell Disease [ Time Frame: Up to One Year ] Genomic DNA extracted from peripheral blood will be analyzed for variable number of tandem repeats (VNTR) to detect donor engraftment in myeloid and lymphoid fractions. Frequency of Idiopathic Pneumonia Syndrome (IPS) [ Time Frame: Up to One Year ] IPS is diagnosed by evidence of widespread (...) hemoglobinopathy, and is in good health; if these criteria are met, they will be allowed to serve as donors. Relatives with sickle cell trait are not excluded as donors. When more than 1 donor is available, the donor with the fewest HLA allele mismatches will be chosen, unless the patient had donor anti-HLA antibodies or there was a medical reason to exclude the donor. If donor anti-HLA antibodies are detected, the next best related match will be chosen. Umbilical cord blood or peripheral blood stem cell

2016 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>